HealthTech Innovations in Infectious Disease Control

July 29, 2024

Infectious diseases have a profound impact on global health, affecting millions of lives and challenging healthcare systems worldwide. From historic pandemics like the Spanish flu to recent outbreaks such as COVID-19, infectious diseases have consistently tested our ability to respond effectively. Innovations in HealthTech have become crucial in the fight against these diseases, offering new tools and strategies for prevention, detection, and treatment. This blog explores the latest HealthTech innovations in infectious disease control, highlighting their potential to transform public health outcomes.


The Challenge of Infectious Diseases


Infectious diseases continue to be a major global health threat. According to the World Health Organization (WHO), infectious diseases cause millions of deaths annually. The COVID-19 pandemic, for instance, has resulted in over 6 million deaths worldwide and disrupted economies and societies on an unprecedented scale. Similarly, diseases like Ebola, Zika, and influenza have caused significant morbidity and mortality, highlighting the need for effective control measures.


Traditional methods of infectious disease control, such as vaccination, quarantine, and sanitation, have been vital in managing outbreaks. However, these methods often face limitations, such as delayed detection, inadequate response capacity, and logistical challenges. Innovations in HealthTech offer new avenues to overcome these barriers and enhance our ability to control infectious diseases.


Digital Surveillance and Early Warning Systems


Digital surveillance is a cornerstone of modern infectious disease control. It involves the use of digital tools and platforms to monitor disease activity, detect outbreaks, and provide early warnings. HealthMap and BlueDot are examples of digital platforms that aggregate data from various sources, including social media, news reports, and official health channels, to identify potential outbreaks.


HealthMap, developed by researchers at Boston Children’s Hospital, uses real-time data analytics to monitor disease outbreaks globally. During the COVID-19 pandemic, HealthMap provided early warnings about the spread of the virus, allowing health authorities to take proactive measures. Similarly, BlueDot, a Canadian startup, uses artificial intelligence (AI) to analyze global travel patterns and disease reports, successfully predicting the spread of infectious diseases like Zika and COVID-19.


Case studies demonstrate the effectiveness of early warning systems in detecting outbreaks. For example, during the 2014 Ebola outbreak in West Africa, digital surveillance tools played a crucial role in tracking the spread of the virus and coordinating response efforts. By providing timely information, these tools enable health authorities to implement targeted interventions and prevent widespread transmission.


Diagnostic Innovations


Advances in diagnostic technologies have revolutionized infectious disease detection. Point-of-care testing (POCT) and rapid diagnostic tests (RDTs) offer quick and accurate diagnosis, enabling timely treatment and reducing the spread of infections. Innovations such as CRISPR-based diagnostics and mobile labs have further enhanced diagnostic capabilities.


CRISPR-based diagnostics leverage the gene-editing technology CRISPR to detect specific genetic sequences associated with pathogens. These tests are highly sensitive and can provide results within minutes. Mobile labs, equipped with advanced diagnostic tools, can be deployed to remote and resource-limited settings, improving access to testing during outbreaks.


For instance, during the COVID-19 pandemic, Abbott’s ID NOW rapid test provided results in just 15 minutes, significantly enhancing testing capacity. Another notable example is the GeneXpert system, which offers rapid molecular testing for diseases like tuberculosis and HIV. These innovations have improved disease detection and enabled health systems to respond more effectively to outbreaks.


Telehealth and Remote Monitoring


Telehealth has emerged as a vital tool in managing infectious diseases, especially during the COVID-19 pandemic. It enables remote consultations, reducing the risk of transmission and ensuring continuity of care. Telehealth platforms facilitate virtual doctor-patient interactions, remote monitoring, and the delivery of healthcare services to patients in isolation or quarantine.


Remote monitoring technologies, such as wearable devices and mobile health apps, allow healthcare providers to track patients’ health status in real-time. For example, during the COVID-19 pandemic, the Oura ring, a wearable device, was used to monitor the vital signs of healthcare workers, helping to detect early symptoms of the virus.


Telehealth platforms like Teladoc and Amwell have seen a surge in adoption, providing virtual care to millions of patients. These platforms have been instrumental in managing chronic diseases, mental health issues, and routine healthcare needs, while minimizing the risk of infection. The use of telehealth and remote monitoring has enhanced healthcare access, improved patient outcomes, and optimized resource utilization.


AI and Machine Learning in Predictive Analytics


Artificial intelligence (AI) and machine learning (ML) have transformed predictive analytics in infectious disease control. These technologies analyze vast amounts of data to identify patterns, predict disease spread, and inform public health responses. AI-driven predictive models and risk mapping tools provide valuable insights for decision-makers.


For instance, Google’s AI-based flu prediction model, Flu Trends, utilized search query data to predict flu outbreaks with remarkable accuracy. Similarly, the COVID-19 Mobility Data Network, a collaboration between tech companies and academic institutions, used mobile phone data to model the spread of COVID-19 and inform policy decisions.


Case studies highlight the impact of AI in improving public health responses. During the Zika virus outbreak, researchers at Northeastern University developed an AI model that predicted the spread of the virus based on climate and travel data. This information enabled health authorities to allocate resources and implement preventive measures in high-risk areas.


AI and ML have the potential to revolutionize infectious disease control by providing real-time insights, optimizing resource allocation, and enhancing the effectiveness of interventions. As these technologies continue to evolve, their applications in public health will expand, offering new opportunities to combat infectious diseases.


Vaccine Development and Distribution


Vaccination is one of the most effective strategies for controlling infectious diseases. Innovations in vaccine development, such as mRNA technology and nanoparticle vaccines, have accelerated the production of safe and effective vaccines. The rapid development and deployment of COVID-19 vaccines exemplify the potential of these innovations.


mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, use synthetic messenger RNA to instruct cells to produce a protein that triggers an immune response. These vaccines were developed and approved in record time, demonstrating the potential of mRNA technology to address future pandemics. Nanoparticle vaccines, which use nanoparticles to deliver antigens, offer another promising approach to vaccine development.


Efficient vaccine distribution and monitoring are critical to achieving widespread immunity. Digital tools, such as vaccine management platforms and cold chain monitoring systems, ensure the safe and timely delivery of vaccines. For example, the Vaccine Management System (VMS) developed by the Indian government has streamlined the distribution of COVID-19 vaccines, improving access and equity.


Successful vaccine rollouts, such as the polio vaccination campaign and the COVID-19 vaccination drive, highlight the importance of coordinated efforts and technological innovation in achieving public health goals. These initiatives have saved millions of lives and prevented the spread of infectious diseases, underscoring the value of vaccines in disease control.


HealthTech Solutions for Public Health Education


Public health education is essential for disease prevention and control. Digital tools and platforms, such as mobile apps and social media campaigns, have enhanced public health communication, reaching diverse audiences and disseminating vital information.


During the COVID-19 pandemic, the World Health Organization (WHO) launched the WHO Academy app, providing up-to-date information and guidance to healthcare workers and the general public. Social media platforms, such as Facebook and Twitter, have been used to combat misinformation and promote health behaviors, such as vaccination and social distancing.


Case studies of effective public health education initiatives demonstrate the impact of digital communication. For instance, the Pulse app, developed by UNICEF, provides real-time information on health emergencies and disease outbreaks to communities in Africa. This app has improved health literacy and enabled timely responses to public health threats.


Digital health education tools have the potential to enhance public awareness, promote preventive behaviors, and support disease control efforts. By leveraging these tools, health authorities can engage communities, address misinformation, and empower individuals to take proactive steps to protect their health.


Notable Labs: Pioneering HealthTech Innovations in Infectious Disease Control


In the ever-evolving landscape of global health, infectious diseases pose a constant and formidable challenge. The recent COVID-19 pandemic has underscored the critical need for innovative solutions to detect, monitor, and treat infectious diseases swiftly and effectively. At the forefront of this innovation is Notable Labs, a company that leverages advanced genetic and molecular analyses to revolutionize infectious disease control. By integrating these cutting-edge techniques into standard healthcare practices, Notable Labs is setting a new standard for precision medicine in public health.


Notable Labs employs state-of-the-art genetic and molecular analysis techniques to understand and combat infectious diseases at a fundamental level. These analyses allow for the precise identification of pathogens and the understanding of their genetic makeup. This level of detail is crucial for developing targeted treatments and vaccines that can effectively neutralize these pathogens. By collaborating with healthcare providers, Notable Labs ensures that these advanced techniques are seamlessly incorporated into routine healthcare practices, making them accessible and affordable for all patients.


The success of Notable Labs lies in its collaborative approach. By working closely with insurers, healthcare providers, and researchers, the company pioneers innovative healthcare solutions that address the complexities of infectious diseases. This collaboration ensures that the treatments developed are not only scientifically sound but also practical and scalable. It facilitates the creation of comprehensive healthcare solutions that can be rapidly deployed in response to emerging health threats.


At the core of Notable Labs' strategy is a commitment to evidence-based practices. The company places a strong emphasis on collecting and analyzing robust clinical data to support the development of effective healthcare solutions. This data-driven approach ensures that the treatments and interventions proposed are backed by solid scientific evidence, enhancing their efficacy and safety. It also supports the development of reimbursement policies that recognize the value and cost-effectiveness of precision medicine, making these advanced treatments more accessible to patients.


Notable Labs exemplifies the transformative potential of precision medicine. By integrating cutting-edge medical advancements into everyday healthcare, the company significantly improves patient care and health outcomes. Personalized treatments tailored to the genetic and molecular profile of each patient ensure that interventions are more effective and less likely to cause adverse effects. This personalized approach not only enhances patient outcomes but also optimizes resource utilization, reducing the overall burden on healthcare systems.


As a leader in the field, Notable Labs is paving the way for a future where personalized healthcare is the norm. The company's innovative approach ensures that each patient receives the most effective and individualized treatment possible. This level of care sets a new standard for healthcare, one where advanced genetic and molecular analyses are routinely used to inform treatment decisions. It marks a significant shift from the one-size-fits-all approach to a more personalized, patient-centric model of care.


The integration of HealthTech innovations into infectious disease control represents a significant advancement in medical science. Companies like Notable Labs are leading this charge, demonstrating the profound impact that precision medicine can have on improving patient outcomes and making healthcare more efficient and effective. By harnessing advanced genetic and molecular analyses, Notable Labs is revolutionizing the way we detect, monitor, and treat infectious diseases, setting a new standard for healthcare worldwide. As we look to the future, the continued support and investment in innovative HealthTech solutions will be crucial in addressing the ongoing challenges posed by infectious diseases and improving global health outcomes.


Challenges and Ethical Considerations


Implementing HealthTech solutions in infectious disease control presents several challenges and ethical considerations. Data privacy and security are paramount, as the collection and sharing of health data raise concerns about confidentiality and consent. Ensuring equitable access to technology and addressing disparities in healthcare delivery are also critical.


Regulatory and compliance hurdles can impede the adoption of HealthTech innovations. Navigating complex regulatory environments and obtaining approvals for new technologies require significant time and resources. Strategies for overcoming these challenges include engaging stakeholders, advocating for supportive policies, and fostering collaboration between public and private sectors.


Ethical considerations, such as obtaining informed consent and ensuring fairness in the distribution of resources, must be addressed to maintain public trust and uphold ethical standards. Transparent communication and community engagement are essential to addressing ethical concerns and promoting the responsible use of technology.


Future Trends and Innovations


The future of HealthTech in infectious disease control is promising, with emerging trends and innovations poised to transform public health. Advances in AI, machine learning, and digital health tools will enhance predictive analytics, improve disease detection, and optimize response strategies.

Wearable devices and remote monitoring technologies will continue to evolve, offering new opportunities for real-time health monitoring and personalized care. Innovations in telehealth and mobile health will expand access to healthcare services, particularly in remote and underserved areas.


Collaboration between global health organizations, governments, and the private sector will drive the development and implementation of HealthTech solutions. Initiatives such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the Global Health Security Agenda (GHSA) exemplify the power of collective action in addressing global health challenges.


Predictions for the next decade include the widespread adoption of digital surveillance systems, the integration of AI in public health decision-making, and the development of next-generation vaccines. These advancements will enhance our ability to prevent, detect, and respond to infectious diseases, ultimately improving global health outcomes.


Conclusion


HealthTech innovations are revolutionizing infectious disease control, offering new tools and strategies to combat global health threats. From digital surveillance and diagnostic technologies to telehealth and AI-driven predictive analytics, these innovations have the potential to transform public health and improve patient outcomes.


As we look to the future, it is essential to support and invest in HealthTech solutions that address infectious disease challenges. By leveraging technology and fostering collaboration, we can enhance our capacity to prevent and control infectious diseases, ensuring a healthier and more resilient world for all.

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts